Delayed commercialization of the sustainable and regenerative medicine-related businesses
First written in FY2023-Q2. 5 of 14 entries say "Mitigated", first in FY2024-Q1. Latest entry: 2026-11-13.
No other company in this theme has enough history to compare yet.
- FY2026WorsenedAnnual report
「In addition, sales of environmental equipment and other products, which were newly added to this segment from the previous fiscal year, were deferred to the following fiscal year because delivery from the manufacturer of the Bio Composter environmental equipment scheduled for sale was substantially delayed.」
Although microalgae research and development progressed, the recording of revenue was deferred to the following fiscal year due to delays in deliveries of environmental equipment. Revenue from the Sustainable Business was ¥7,943 thousand, and the operating loss was ¥64,197 thousand. - 2026-06-04WorsenedGeneral Meetings of Shareholders
「依然として投資フェーズにあり、本格的な収益計上までには、なお時間を要するものと判断いたしました。」
再生医療関連事業及びサスティナブル事業について、投資フェーズが継続し、本格収益化に時間を要すると記載され、関連資産の減損損失も計上されている。 - FY2026-H1Research and development progress alongside delays in product salesAnnual report
「In the microalgae business, which is the core business of this segment, steady progress was made in research and development, including the successful realization of high-concentration cultivation of spirulina, which contains abundant nutritional and health-promoting components and is expected to have strong commercialization potential in the future, and chinorimo, which is viewed as a promising future source of pharmaceutical and cosmetic ingredients.」
Although research and development progressed, revenue was limited to ¥919 thousand due to delays in deliveries of environmental equipment, among other factors, and the operating loss widened from ¥28,517 thousand in the same period of the previous year to ¥29,917 thousand. Delays in commercialization and monetization continue. - FY2025-H1Continued monetization delays and a narrower lossAnnual report
「However, during the current fiscal year, the products were still in the development stage, so full-scale revenue had not yet been recorded, and irregular consulting engagements and similar work accounted for most of the revenue. As a result, revenue was ¥3.203 million, up ¥348,000 year on year, and the operating loss was ¥28.517 million, compared with an operating loss of ¥36.817 million in the same period of the previous year.」
In the sustainable business, inquiries and business leads increased and the operating loss narrowed from the same period of the previous year, but the products remain in the development stage and have not yet generated full-scale revenue. Progress toward commercialization coexists with delays in monetization. - FY2024MitigatedAnnual report
「As a result of ongoing sales activities for microalgae cultivation equipment, inquiries from companies and other customers increased and new transactions began. As a result, revenue was ¥42.194 million, up ¥31.411 million from the previous consolidated fiscal year, and the operating loss was ¥58.033 million, compared with a loss of ¥61.712 million in the previous consolidated fiscal year.」
In the sustainable business, inquiries increased and new transactions continued to begin, resulting in higher revenue and a narrower operating loss. Commercialization is progressing, but the business has not yet reached monetization. - FY2024-Q3MitigatedAnnual report
「As a result of ongoing sales activities for microalgae cultivation equipment, inquiries from companies and other customers increased and new transactions began. As a result, revenue was ¥36.094 million, up ¥35.515 million year on year, and the operating loss was ¥45.252 million, compared with an operating loss of ¥52.440 million in the same quarter of the previous year.」
In the sustainable business, inquiries increased and new transactions continued to begin, resulting in higher revenue and a narrower operating loss than in the same period of the previous year. Progress toward commercialization was evident, although an operating loss remained. - FY2024-Q2Commercialization progress and widening losses coexistAnnual report
「As a result of ongoing sales activities, we achieved a certain level of recognition, inquiries from companies and other customers increased, and new transactions began. As a result, revenue was ¥2.854 million, up ¥2.754 million year on year, and the operating loss was ¥36.817 million, compared with an operating loss of ¥33.742 million in the same quarter of the previous year.」
In the sustainable business, inquiries increased and new transactions continued to begin, while revenue remained limited to ¥2.854 million and the operating loss widened from the same period of the previous year. Progress toward commercialization coexisted with delays in monetization. - FY2024-Q1MitigatedAnnual report
「As a result of ongoing sales activities, we achieved a certain level of recognition, inquiries from companies and other customers increased, and new transactions began. As a result, revenue was ¥2.294 million, up ¥2.294 million year on year, and the operating loss was ¥17.288 million, compared with an operating loss of ¥17.028 million in the same quarter of the previous year.」
In the sustainable business, the company reported increased inquiries from companies and other customers and the start of new transactions, indicating progress toward commercialization. Meanwhile, the operating loss continued. - FY2023Commercialization progress and delays coexistAnnual report
「Because commercialization of the sustainable business was delayed」
While commercialization of the regenerative medicine-related business is said to have progressed rapidly through the acquisition of RMDC as a wholly owned subsidiary, delays in commercialization of the sustainable business continue to be cited. - FY2023-Q3RestatedAnnual report
「In the sustainable and regenerative medicine-related businesses, which we have positioned as key future growth areas and in which we are actively conducting new research, we have received inquiries from multiple customers. However, because these initiatives also represent new businesses for customer companies, their consideration is taking time, delaying commercialization. As a result, revenue was ¥579,000, up ¥579,000 year on year, and the operating loss was ¥52.440 million, compared with a loss of ¥63.475 million in the same quarter of the previous year.」
Although the company has received inquiries from multiple customers, customer consideration is taking time and commercialization delays continue. Revenue was limited to ¥579,000, while the operating loss narrowed from the same period of the previous year. - FY2023-Q2First statedAnnual report
「In the sustainable and regenerative medicine-related businesses, which we have positioned as key future growth areas and in which we are actively conducting new research, we have received inquiries from multiple customers. However, because these initiatives also represent new businesses for customer companies, their consideration is taking time, delaying commercialization. As a result, revenue was ¥100,000, up ¥100,000 year on year, and the operating loss was ¥33.742 million, compared with a loss of ¥28.978 million in the same quarter of the previous year.」
The company states that, although it has received inquiries from multiple customers, customer consideration is taking time and commercialization has been delayed. Revenue was limited to ¥100,000, and the company recorded an operating loss of ¥33.742 million.